Progenika Licenses Protein Array Tech from Harvard Spin-out Auguron | GenomeWeb
NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
 
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.